Establishing a Proteomics-Based Signature of AKR1C3-Related Genes for Predicting the Prognosis of Prostate Cancer
暂无分享,去创建一个
Jing Li | Tianyu Zhao | Xiaoli Cui | Yaru Wang | Jipeng Ding | C. Li | Zhou Yao | Jiahui Guo | Jiahui Guo
[1] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[2] Yandong Miao,et al. Prognostic implications of ferroptosis-associated gene signature in colon adenocarcinoma , 2021, World journal of clinical cases.
[3] S. Tavaré,et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma , 2021, Cancer cell.
[4] C. Liang,et al. Identification of a Costimulatory Molecule-Related Signature for Predicting Prognostic Risk in Prostate Cancer , 2021, Frontiers in Genetics.
[5] H. Maecker,et al. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC) , 2021, Journal for ImmunoTherapy of Cancer.
[6] Tiancheng Xie,et al. Identification and Validation of a Prognostic Signature for Prostate Cancer Based on Ferroptosis-Related Genes , 2021, Frontiers in Oncology.
[7] S. Sakaguchi,et al. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells , 2021, Proceedings of the National Academy of Sciences.
[8] Da-peng Wei,et al. CDC20 and PTTG1 are Important Biomarkers and Potential Therapeutic Targets for Metastatic Prostate Cancer , 2021, Advances in Therapy.
[9] F. Jadidi-Niaragh,et al. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. , 2021, Life sciences.
[10] S. Tsoka,et al. Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action , 2021, European journal of immunology.
[11] Qiaolin Xu,et al. Inhibition of SRSF3 Alleviates Proliferation and Migration of Gastric Cancer Cells by Regulating the PI3K/AKT/mTOR Signalling Pathway. , 2021, Folia biologica.
[12] Henk G van der Poel,et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. , 2020, European urology.
[13] Peifeng Li,et al. Emerging Roles of SRSF3 as a Therapeutic Target for Cancer , 2020, Frontiers in Oncology.
[14] Jin-jian Lu,et al. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. , 2020, Pharmacology & therapeutics.
[15] Weimin Cai,et al. SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer , 2020, Theranostics.
[16] Xiao Zhi Qiu,et al. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer , 2019, Molecular Cancer Therapeutics.
[17] O. Ogawa,et al. Consecutive Prostate Cancer Specimens Revealed Increased Aldo–Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer , 2019, Journal of clinical medicine.
[18] Hai Huang,et al. Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells , 2019, EBioMedicine.
[19] H. Hsu,et al. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer , 2019, Molecular Cancer.
[20] Z. Tomková,et al. RHOA and mDia1 Promotes Apoptosis of Breast Cancer Cells Via a High Dose of Doxorubicin Treatment , 2019, Open life sciences.
[21] M. Mohsenzadegan,et al. A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer. , 2019, Current drug targets.
[22] L. Scott. Enzalutamide: A Review in Castration-Resistant Prostate Cancer , 2018, Drugs.
[23] T. Yi,et al. Series test of cluster and network analysis for lupus nephritis, before and after IFN‐K‐immunosuppressive therapy , 2018, Nephrology.
[24] Shan Xu,et al. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling. , 2018, Urologic oncology.
[25] Zhongqi Cui,et al. Combining multi‐dimensional data to identify a key signature (gene and miRNA) of cisplatin‐resistant gastric cancer , 2018, Journal of cellular biochemistry.
[26] G. van der Pluijm,et al. Protocols for Migration and Invasion Studies in Prostate Cancer. , 2018, Methods in molecular biology.
[27] D. Choi,et al. The mitochondrial hinge protein, UQCRH, is a novel prognostic factor for hepatocellular carcinoma , 2017, Cancer medicine.
[28] Wen-Jye Lin,et al. Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22–CCR4 axis , 2016, Oncotarget.
[29] S. Zhang,et al. Identification of ubiquinol cytochrome c reductase hinge (UQCRH) as a potential diagnostic biomarker for lung adenocarcinoma , 2016, Open Biology.
[30] Yusuke Nakamura,et al. PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP , 2015, Oncotarget.
[31] Yezi Zhu,et al. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. , 2015, Cancer research.
[32] J. Vandesompele,et al. Early Targets of miR-34a in Neuroblastoma* , 2014, Molecular & Cellular Proteomics.
[33] Yuantong Tian,et al. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression , 2014, Diagnostic Pathology.
[34] J. Bono,et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. , 2014, European journal of cancer.
[35] N. Cox,et al. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines , 2014, Genome Biology.
[36] L. Walker. Treg and CTLA-4: Two intertwining pathways to immune tolerance , 2013, Journal of autoimmunity.
[37] J. Schalken,et al. Aldo-keto Reductase Family 1 Member C3 (AKR1C3) Is a Biomarker and Therapeutic Target for Castration-Resistant Prostate Cancer , 2012, Molecular medicine.
[38] Yan Ma,et al. Prospective nested case–control study of feature genes related to leukemic evolution of myelodysplastic syndrome , 2012, Molecular Biology Reports.
[39] K. Aozasa,et al. Infiltration of tumour‐associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer , 2011, BJU international.
[40] L. V. D. Heuvel,et al. The human nuclear-encoded acyl carrier subunit (NDUFAB1) of the mitochondrial complex I in human pathology , 1999, Journal of Inherited Metabolic Disease.
[41] D. Gerloff,et al. Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells , 2001, Chromosoma.